Study guide

1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

Key Takeaways Explain This Topic AI

Li-Fraumeni syndrome (TP53) is autosomal dominant with a broad early-onset core tumor spectrum—soft-tissue and osteosarcoma, premenopausal breast cancer, brain tumors, adrenocortical carcinoma, and leukemias—requiring cautious radiation and whole-body surveillance concepts

Von Hippel–Lindau (VHL) features hemangioblastomas, clear-cell renal cell carcinoma, pheochromocytoma, and endolymphatic sac tumors with genotype-informed pheochromocytoma risk counseling

MEN1 (MEN1) centers on parathyroid, pituitary, and enteropancreatic neuroendocrine tumors; MEN2 (RET) centers on medullary thyroid carcinoma with gene-specific prophylactic thyroidectomy timing and pheochromocytoma/hyperparathyroidism patterns by MEN2A/2B

NF1 (NF1) is common, AD, with café-au-lait macules, neurofibromas, and tumor risks including MPNST and optic pathway glioma; NF2-related schwannomatosis (NF2) is dominated by bilateral vestibular schwannomas

Diagnostic strategy matches hallmark tumors to syndrome genes, confirms germline variants, then applies syndrome-specific surveillance—avoid one-size-fits-all “hereditary cancer” scripts

Last updated: August 2026

1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

Quick Answer: Match hallmark tumors to genes: TP53 (LFS core cancers), VHL (hemangioblastoma/RCC/pheo), MEN1 (3 Ps), RET (MTC ± pheo/HPTH; MEN2B phenotype), NF1 (CALMs/neurofibromas/MPNST), NF2 (bilateral vestibular schwannomas). All major entities here are autosomal dominant with syndrome-specific surveillance.

After HBOC and Lynch/polyposis, Domain 1C expects fluent recognition of rarer but high-stakes cancer predisposition syndromes. Exam vignettes often give one pathognomonic tumor (adrenocortical carcinoma in a child; bilateral vestibular schwannomas; medullary thyroid cancer) and ask for the gene, inheritance, or next management concept.

Li-Fraumeni Syndrome (LFS) — TP53

  • Element Board-level content
  • Inheritance Autosomal dominant; TP53 tumor suppressor

Core tumors (“classic”) Soft-tissue sarcoma, osteosarcoma, premenopausal breast cancer, brain tumors, adrenocortical carcinoma (ACC), leukemias

Natural history Very early onset possible; multiple primary cancers common across the lifespan

Diagnostic clues Childhood ACC or choroid plexus carcinoma strongly prompts TP53 evaluation; soft-tissue/osteosarcoma + family pattern

Management Themes

Breast surveillance for women often resembles high-risk protocols (MRI; discussion of risk-reducing mastectomy in shared decision-making).

Whole-body MRI and structured protocols (e.g., “Toronto protocol”–style comprehensive surveillance) appear in LFS care concepts—know that surveillance is multimodal and starts early.

Radiation sensitivity / second-malignancy concern: avoid unnecessary radiation when alternatives exist; therapeutic radiation decisions are oncology-led but counselors flag the issue.

Cascade testing has profound psychosocial implications because of childhood risks and reproductive decisions.

Chompret criteria and classic LFS criteria are clinical selection tools—similar in spirit to Amsterdam for Lynch: helpful, incomplete alone.

Von Hippel–Lindau Disease — VHL

VHL is autosomal dominant. Hallmark lesions:

  • Tumor / feature Notes
  • CNS / retinal hemangioblastomas Cerebellum, brainstem, spine, retina—vision and neurologic morbidity
  • Clear-cell renal cell carcinoma Often multifocal/bilateral; nephron-sparing strategies
  • Pheochromocytoma / paraganglioma Genotype correlates with risk (certain missense variants higher pheo risk)
  • Pancreatic cysts / NETs Surveillance component
  • Endolymphatic sac tumors Hearing loss clue
  • Epididymal / broad ligament cystadenomas Benign but syndromic clues

Counseling centers on lifelong coordinated surveillance (ophthalmology, CNS imaging, abdominal imaging, biochemical pheo screening) rather than a single prophylactic surgery. Distinguish VHL from other hereditary pheo/PGL syndromes ( SDHx , RET , NF1 , MAX , TMEM127 ) when the vignette is pheo-first.

  • Multiple Endocrine Neoplasia
  • MEN1 — MEN1
  • “3 P” core Detail
  • Parathyroid Primary hyperparathyroidism—often multigland; earliest/most penetrant feature
  • Pituitary Prolactinoma and other adenomas
  • Enteropancreatic neuroendocrine tumors Gastrinoma (Zollinger-Ellison), insulinoma, others—malignant potential

Additional features can include foregut carcinoids, adrenocortical lesions, and facial angiofibromas/collagenomas. Inheritance is AD. Management is biochemical and imaging surveillance plus targeted surgery—not one universal risk-reducing operation like MEN2 thyroidectomy.

MEN2 — RET

Subtype Hallmarks Counseling anchor

MEN2A Medullary thyroid carcinoma (MTC), pheo, hyperparathyroidism RET codon correlates with MTC aggressiveness and prophylactic thyroidectomy timing

MEN2B (MEN3) Very early/aggressive MTC, pheo, mucosal neuromas, marfanoid habitus, ganglioneuromatosis Highest-risk RET variants (e.g., p.Met918Thr classically)—thyroidectomy discussed in infancy in specialty care

FMTC MTC-predominant familial pattern Still RET -related spectrum

Prophylactic thyroidectomy timed by RET genotype is a defining MEN2 management concept and a frequent exam target. Always screen for pheochromocytoma before thyroid surgery when indicated—anesthesiology/surgical safety point genetic counselors should mention in preoperative counseling coordination.

Neurofibromatosis Type 1 and NF2-Related Schwannomatosis

  • Feature NF1 ( NF1 ) NF2 ( NF2 , Merlin)
  • Inheritance AD; ~50% de novo AD; frequent de novo

Cutaneous Café-au-lait macules, skinfold freckling, cutaneous neurofibromas Less “classic CALM” story; skin schwannomas possible

Hallmark tumors Optic pathway glioma, plexiform neurofibromas, malignant peripheral nerve sheath tumor ( MPNST ) Bilateral vestibular schwannomas ; other schwannomas, meningiomas, ependymomas

Other Learning differences, skeletal dysplasia, hypertension/pheo (less common than VHL/MEN2) Hearing loss, balance problems dominate quality of life

Cancer counseling MPNST risk education; breast cancer risk modestly increased in women—surveillance awareness Tumor burden management; hearing preservation strategies

Clinical diagnostic criteria (NIH/revised) still matter because many NF1 diagnoses are clinical; molecular confirmation helps atypical cases and cascade testing. Schwannomatosis ( SMARCB1 / LZTR1 ) is a related differential when vestibular schwannomas are absent.

Other High-Yield Predisposition Pointers (Brief)

Syndrome Gene(s) One-line hallmark

Gorlin (nevoid BCC) PTCH1 , SUFU Multiple basal cell carcinomas, jaw keratocysts, medulloblastoma risk ( SUFU )

  • Cowden / PTEN hamartoma PTEN Macrocephaly, hamartomas, breast/thyroid/endometrial risks
  • Hereditary retinoblastoma RB1 Childhood retinoblastoma ± later sarcoma risk; radiation caution
  • Familial atypical mole–melanoma CDKN2A Melanoma ± pancreatic cancer risk discussions
  • Hereditary pheo/PGL SDHB/C/D , etc. SDHB higher malignancy concern

Use these when a vignette sits outside HBOC/Lynch/LFS/VHL/MEN/NF—but master the primary five first.

Cross-Cutting Diagnostic and Counseling Strategy

Hallmark tumor → syndrome shortlist (ACC child → LFS; MTC → RET ; hemangioblastoma + RCC → VHL; bilateral vestibular schwannomas → NF2).

Offer germline testing with pretest counseling about childhood-onset implications when relevant ( TP53 , RET MEN2B, RB1 ).

Assign syndrome-specific surveillance (not generic “annual mammogram only”).

Address risk-reducing surgery where established (notably genotype-guided thyroidectomy in MEN2; selective discussions in LFS breast risk).

Implement cascade testing and coordinate multidisciplinary care (endo, neurosurgery, ophthalmology, oncology).

  • Syndrome Inheritance Signature teaching tumor(s) Signature management concept
  • LFS AD ( TP53 ) Sarcoma, ACC, early breast, brain, leukemia Comprehensive surveillance; radiation caution
  • VHL AD ( VHL ) Hemangioblastoma, ccRCC, pheo Lifelong multi-organ surveillance
  • MEN1 AD ( MEN1 ) Parathyroid, pituitary, pancreatic NET Biochemical/imaging surveillance
  • MEN2 AD ( RET ) MTC ± pheo ± HPTH Genotype-timed prophylactic thyroidectomy
  • NF1 AD ( NF1 ) OPG, plexiforms, MPNST Tumor vigilance; clinical + molecular diagnosis
  • NF2 AD ( NF2 ) Bilateral vestibular schwannomas Hearing-preserving tumor management

These syndromes repay pattern recognition: one hallmark feature correctly identified often unlocks the entire counseling plan.